Therapeutic Efficacy of Oxazaphosphorines by Immunomodulation
Cyclophosphamide and a few related compounds of the class of oxazaphosphorines are widely used in the chemotherapy of malignant diseases. Their antitumour efficacy is based on their cytotoxic activity against quickly proliferating cells. Beside this, these agents are strong immunosuppressants and a particularly high sensitivity of antibody-producing, proliferating B cells was postulated (1). In contrast, it could be shown that cyclophosphamide in non-toxic doses enhanced delayed-type hypersensitivity reactions, which indicated a selective effect of cyclophosphamide on T cells (2,3).
KeywordsAntitumour Efficacy Modify Cell Surface Human Peripheral Mononuclear Cell Adjuvant Combination Chemotherapy Host Antitumor Immunity
Unable to display preview. Download preview PDF.
- 1.I. McConnell, A. Munro, and H. Waldman, “The Immune System: A Course on the Molecular and Cellular Basis of Immunity”, The Alden Press, Oxford (1981).Google Scholar
- 4.D. Bernd, M. J. Mastrangelo, P. F. Engstrom, A. Paul, and H. Maguire, Augmentation of the human immune response by cyclophosphamide, Cancer Res., 42: 4862–4866 (1982).Google Scholar
- 5.D. Bernd, H. C. Maguire, Jr., and M. J. Mastrangelo, Impairment of concanavalin A-inducible suppressor activity following administration of cyclophosphamide to patients with advanced cancer, Cancer Res., 44: 1275–1280 (1984).Google Scholar
- 6.R. C. Bast, Jr., E. L. Reinherz, C. Mayer, P. Lavin, and S. F. Schlossman, Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes, Clin. Immunol. Immunopathol., 28: 101–114 (1983).Google Scholar
- 8.H. Grunicke, H. Putzer, F. Scheidl, and E. Wolff-Schreiner, The cell surface as a target for alkylating agents, in: “The control of tumour growth and its biological bases”, W. Davis, C. Maltoni, and S. Tanneberger, eds., Akademie-Verlag, Berlin (1983).Google Scholar
- 12.Proc. Satellite Meeting 10th Int. Symposium on the Biological Characterization of Human Tumors, Brighton, Invest. New Drugs, 2: 129–259 (1984).Google Scholar
- 14.Internal Report, Asta-Werke AGGoogle Scholar
- 15.K. Powell, A. Buzdar, T. Smith, and G. Blumenschein, Subsequent malignant neoplasma in stage II, III breast cancer patients treated with and without adjuvant combination chemotherapy, Proc. ASCO, 1:C-301 (1982).Google Scholar